Questions remain regarding whether both CD8+ and CD4+ epitopes are necessary [220] and whether vaccine-induced CD4+ T-cell responses can promote CD8 + T-cell priming and differentiation for improved tumor control [311–313]. Here, CD4 is linked to neoplasm.